ClinicalTrials.gg

Program

pivekimab sunirine

Also written as “Pivekimab Sunirine” and “IMGN632”.

Its studies are mostly in Leukemia, Myeloid, Acute · Blastic Plasmacytoid Dendritic Cell Neoplasm, led by AbbVie.

Furthest: phase 3, since May 6, 20264 company-led studies, 4 open or runningNext primary completion: Feb 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie44 open or runningphase 3since May 6, 2026Dec 21, 2017Feb 2027phase 2 · NCT04086264

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 21, 2017First study: phase 2 study in Blastic Plasmacytoid Dendritic Cell NeoplasmFirst studyNCT03386513 · 179 enrolled · United States, France, Germany and more
  2. Sep 9, 2019Phase 2 study in Leukemia, Myeloid, AcuteNCT04086264 · 218 enrolled · United States, France, Germany and more
  3. Dec 15, 2025Phase 1 study in Leukemia, Myeloid, AcuteNCT07306832 · 18 planned · United States, Australia, France and more
  4. May 6, 2026Phase 3 study in Leukemia, Myeloid, AcutePhase 3 reachedNCT07581002 · 660 planned · United States, Austria, France and more

Ahead

  1. Feb 2027Primary completion: phase 2 study in Leukemia, Myeloid, AcuteNCT04086264
  2. Apr 2028Primary completion: phase 1 study in Leukemia, Myeloid, AcuteNCT07306832
  3. Jun 2032Primary completion: phase 3 study in Leukemia, Myeloid, AcuteNCT07581002

TargetBeta

IL3RA →read by rule
“Interleukin-3 receptor subunit alpha binding agent”ChEMBL 37, by rule

Other programs on IL3RA

ProgramCompanyFurthest phaseStudies
relmapirazinrulemedibeaconphase 38

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07581002Leukemia, Myeloid, Acute · United States, Austria, France and more3RecruitingJun 2032660
NCT07306832Leukemia, Myeloid, Acute · United States, Australia, France and more1RecruitingApr 202818
NCT04086264Leukemia, Myeloid, Acute · United States, France, Germany and more2Active, not recruitingFeb 2027218
NCT03386513Blastic Plasmacytoid Dendritic Cell Neoplasm · United States, France, Germany and more2Active, not recruitingOct 2, 2024179

How it is read

Names in the registry

  • “Pivekimab Sunirine”, 2 entries
  • “IMGN632”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.